Exceptions for rape and incest in states with trigger laws outlawing abortion may be impossible to implement effectively; Supreme Court determines Medicare’s payments are lawful in a blow to hospitals that had pay cuts; a court ruled that Juul could continue selling e-cigarettes temporarily.
In the wake of Friday’s Supreme Court ruling overturning Roe v Wade, some providers believe that, in states with trigger laws outlawing abortions except for special cases such as rape and incest, it will be difficult to prove that a woman needs an abortion for those reasons, putting health care providers at risk of a prison sentence. The impracticality of these exemptions could prompt abortion clinics to move across state lines, which would lead to millions of women losing access in their state. Abortion rights advocates believe some ob-gyns with a private practice could provide a prescription to abortion pills for women who are pregnant due to incest or rape.
The Supreme Court ruled in a 5-4 decision that the Medicare payment system for safety-net providers was lawful, which is a major setback for hospitals that have experienced pay cuts. The ruling allows HHS to continue making disproportionate share payments to hospitals that serve many low-income patients based on the number of patients treated who meet the basic criteria for Medicare, regardless of primary insurance. The majority opinion, written by Justice Elena Kagan, claimed that the point of the statute was not to pay as much money as possible to the hospitals but instead to compensate hospitals for serving low-income patients.
A federal court in Florida ruled that Juul could continue to sell its e-cigarettes while it awaits the results of a challenge to an FDA ban on its products. The company, which was ordered to shut down all US sales on June 23 and is reportedly considering bankruptcy, plans to challenge the ban this week. The ruling gives Juul at least 2 weeks to continue sales while the court reviews the full request by Juul for an emergency stay, which will not be processed until at least mid-July. The FDA had banned Juul products because of concerns about toxicology data from the company.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines
September 6th 2025National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO), and the American College of Chest Physicians (CHEST) offer complementary yet distinct frameworks for lung cancer care, reflecting differences in evidence evaluation, regional adaptation, and policy integration.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More